Swedish pharmaceutical company Medivir AB (STO:MVIR) announced on Wednesday that it has received a European patent covering the combination of fostroxacitabine bralpamide (fostrox) and lenvatinib (Lenvima) for treating hepatocellular carcinoma (HCC) and liver metastases.
This patent grants market exclusivity until April 2041, reinforcing Medivir's intellectual property position in liver cancer therapeutics.
The patent approval is part of Medivir's strategy to protect clinically significant combinations involving fostrox in liver cancer treatment. It follows positive final data from the phase 1b/2a study presented at the EASL Liver Cancer Summit and supports the company's ongoing efforts to initiate a phase 2b study in second-line HCC.
Insilico Medicine names new vice president, Clinical Development – Oncology
Kelun-Biotech reports fourth indication for sac-TMT approved by NMPA in HR+/HER2- breast cancer
Delonix Bioworks gets IND clearance for DX-104 in China
Innovent Biologics collaborates with Eli Lilly to develop new oncology and immunology treatments
K36 Therapeutics completes first patient cohort dosing for Phase 1 trial of KTX-2001
Cumberland Pharmaceuticals secures FDA Fast Track status for DMD heart‑disease therapy ifetroban
Hologic receives FDA approval for Aptima HPV assay as primary screening option
Cizzle Biotechnology secures Canadian patent for lung cancer biomarker test
Biosion reports first patient dosed in Phase 1a/1b trial of BSI-082
Relay Therapeutics wins FDA breakthrough status for zovegalisib in breast cancer treatment
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Valneva and Instituto Butantan launch pilot chikungunya vaccination campaign in Brazil
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Astrazeneca Imfinzi perioperative regimen gains positive EU CHMP opinion in early gastric cancer